Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...

An estimated 1 in 8,000 individuals, or 870,000 people worldwide, are affected by Facioscapulohumeral muscular dystrophy ...

Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

Delpacibart zotadirsen is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy.

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...

Dalton “D” Harvey has dreamed of being a firefighter his entire life. Escambia County firefighters helped make that dream ...

Avidity Biosciences (RNA) announced its progress and planning for a transformational year in 2025. These major anticipated milestones include ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...

A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its ...

After disappointing Phase IIb results for avicursen last month, Percheron will adopt a three-pronged business strategy.